{
    "hands_on_practices": [
        {
            "introduction": "The reliability of any Minimum Inhibitory Concentration (MIC) assay hinges on standardization, and no variable is more critical than the starting bacterial inoculum. This exercise provides hands-on practice with the fundamental dilution calculations required to prepare a working inoculum and achieve the precise target bacterial density in the final assay wells. Mastering this process is essential for ensuring that MIC results are reproducible and comparable across different experiments and laboratories .",
            "id": "5220368",
            "problem": "A clinical laboratory is performing a broth microdilution determination of the Minimum Inhibitory Concentration (MIC), defined as the lowest antimicrobial concentration that prevents visible growth of a microorganism after standardized incubation. For reproducibility, the inoculum must be standardized to a target density of $5 \\times 10^{5}$ Colony Forming Units per milliliter (CFU/mL) in each well of a microtiter plate with a total well volume of $100\\,\\mu\\mathrm{L}$.\n\nA starting bacterial suspension has a measured density of $1.5 \\times 10^{8}$ CFU/mL. The protocol uses a serial dilution scheme to prepare the working inoculum: first a $1:10$ dilution, then a $1:15$ dilution, and finally an in-well mixing step in which $50\\,\\mu\\mathrm{L}$ of the diluted inoculum is combined with $50\\,\\mu\\mathrm{L}$ of antimicrobial solution (cell-free), yielding a total in-well volume of $100\\,\\mu\\mathrm{L}$.\n\nStarting from fundamental definitions of number density and conservation under dilution, derive the final in-well inoculum density from the starting suspension and the described dilution scheme. Then compute the expected number of viable cells delivered per well at this final density.\n\nExpress the final requested quantity as CFU and round your answer to four significant figures. Do not include units in your boxed final answer.",
            "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, and objective. It contains all necessary information to derive a unique solution based on fundamental principles of microbiology and laboratory mathematics. No flaws were identified. Therefore, a full solution is provided.\n\nThe problem requires the calculation of two quantities: the final in-well inoculum density and the total number of viable cells, or Colony Forming Units (CFU), delivered to each well. The solution will be derived from the fundamental principle of mass (or number) conservation during a dilution process.\n\nLet $C_{start}$ be the density of the starting bacterial suspension. The problem provides:\n$$C_{start} = 1.5 \\times 10^{8} \\, \\text{CFU/mL}$$\n\nThe protocol involves a sequence of three dilution steps. We will calculate the concentration after each step. A dilution reduces the concentration $C$ by a dilution factor $D$, such that $C_{new} = C_{old} \\times D$. For a volumetric dilution, the factor $D$ is the ratio of the volume of the original solution to the total volume after dilution.\n\n**Step 1: First Dilution**\nThe starting suspension is subjected to a $1:10$ dilution. The dilution factor is $D_1 = \\frac{1}{10}$. The concentration after this step, $C_1$, is:\n$$C_1 = C_{start} \\times D_1 = C_{start} \\times \\frac{1}{10}$$\n\n**Step 2: Second Dilution**\nThe suspension at concentration $C_1$ is then subjected to a $1:15$ dilution. The dilution factor is $D_2 = \\frac{1}{15}$. The concentration of the resulting working inoculum, $C_2$, is:\n$$C_2 = C_1 \\times D_2 = \\left(C_{start} \\times \\frac{1}{10}\\right) \\times \\frac{1}{15} = C_{start} \\times \\frac{1}{150}$$\n\n**Step 3: In-Well Mixing and Dilution**\nIn the final step, a volume $V_{inoculum} = 50\\,\\mu\\mathrm{L}$ of the working inoculum (at concentration $C_2$) is mixed with a volume $V_{antimicrobial} = 50\\,\\mu\\mathrm{L}$ of cell-free antimicrobial solution. The total volume in the well becomes $V_{well}$:\n$$V_{well} = V_{inoculum} + V_{antimicrobial} = 50\\,\\mu\\mathrm{L} + 50\\,\\mu\\mathrm{L} = 100\\,\\mu\\mathrm{L}$$\nThis mixing constitutes a final dilution step. The number of cells is conserved. The number of cells transferred is $N = C_2 \\times V_{inoculum}$. The final concentration in the well, $C_{final}$, is this number distributed over the total volume $V_{well}$.\n$$C_{final} = \\frac{N}{V_{well}} = \\frac{C_2 \\times V_{inoculum}}{V_{well}}$$\nThe dilution factor for this step, $D_{mix}$, is:\n$$D_{mix} = \\frac{V_{inoculum}}{V_{well}} = \\frac{50\\,\\mu\\mathrm{L}}{100\\,\\mu\\mathrm{L}} = \\frac{1}{2}$$\nThus, the final concentration is:\n$$C_{final} = C_2 \\times D_{mix} = \\left(C_{start} \\times \\frac{1}{150}\\right) \\times \\frac{1}{2} = C_{start} \\times \\frac{1}{300}$$\n\nNow, we substitute the value of $C_{start}$ to calculate the final in-well inoculum density, which is the first part of the problem's requirement.\n$$C_{final} = (1.5 \\times 10^{8} \\, \\text{CFU/mL}) \\times \\frac{1}{300} = \\frac{1.5 \\times 10^{8}}{3 \\times 10^{2}} \\, \\text{CFU/mL}$$\n$$C_{final} = 0.5 \\times 10^{6} \\, \\text{CFU/mL} = 5 \\times 10^{5} \\, \\text{CFU/mL}$$\nThis derived final density matches the target density specified in the problem, which confirms the dilution scheme is correctly designed.\n\nThe second part of the problem asks for the expected number of viable cells delivered per well, which we denote as $N_{CFU}$. This is the product of the final density $C_{final}$ and the total well volume $V_{well}$.\n$$N_{CFU} = C_{final} \\times V_{well}$$\nTo perform this calculation, the units must be consistent. We will convert the total well volume from microliters ($\\mu\\mathrm{L}$) to milliliters (mL), using the conversion factor $1 \\, \\text{mL} = 1000 \\, \\mu\\mathrm{L}$.\n$$V_{well} = 100\\,\\mu\\mathrm{L} = 100\\,\\mu\\mathrm{L} \\times \\frac{1\\,\\text{mL}}{1000\\,\\mu\\mathrm{L}} = 0.1\\,\\text{mL} = 10^{-1}\\,\\text{mL}$$\nNow, we can calculate $N_{CFU}$:\n$$N_{CFU} = (5 \\times 10^{5} \\, \\text{CFU/mL}) \\times (10^{-1} \\, \\text{mL})$$\n$$N_{CFU} = 5 \\times 10^{4} \\, \\text{CFU}$$\nThis value is exactly $50000$ CFU. The problem specifies that the final answer should be rounded to four significant figures.\n$$N_{CFU} = 50000 = 5.000 \\times 10^{4}$$",
            "answer": "$$\\boxed{5.000 \\times 10^{4}}$$"
        },
        {
            "introduction": "In an ideal experiment, increasing antimicrobial concentrations produce a clear, monotonic inhibition of microbial growth. However, real-world laboratory results can sometimes present confounding patterns, such as \"skipped wells,\" where growth reappears at a concentration higher than one that showed inhibition. This exercise simulates a common diagnostic challenge, requiring you to analyze an invalid result, deduce the most likely technical causes, and determine the correct course of action, reinforcing the critical importance of data integrity and quality control in clinical decision-making .",
            "id": "5220384",
            "problem": "A clinical laboratory performs a broth microdilution minimum inhibitory concentration (MIC) test according to standard practice: a twofold serial dilution series of a beta-lactam antimicrobial is prepared in cation-adjusted Mueller–Hinton broth, each well is inoculated to a final standardized density of approximately $5 \\times 10^{5}$ colony-forming units per milliliter (CFU/mL), and the panel is incubated at $35\\,^{\\circ}\\mathrm{C}$ for $16$–$20$ h. The MIC is defined as the lowest antimicrobial concentration that prevents visible growth under correctly executed, standardized conditions.\n\nFor a Klebsiella pneumoniae isolate tested against cefepime, the following readout is observed after $18$ h at $35\\,^{\\circ}\\mathrm{C}$. The growth control shows visible turbidity (growth present) and the sterility control is clear (no growth). The antimicrobial wells read as:\n- $0.06$ $\\mu\\mathrm{g/mL}$: growth present\n- $0.125$ $\\mu\\mathrm{g/mL}$: no visible growth\n- $0.25$ $\\mu\\mathrm{g/mL}$: no visible growth\n- $0.5$ $\\mu\\mathrm{g/mL}$: growth present\n- $1$ $\\mu\\mathrm{g/mL}$: growth present\n- $2$ $\\mu\\mathrm{g/mL}$: no visible growth\n- $4$ $\\mu\\mathrm{g/mL}$: no visible growth\n- $8$ $\\mu\\mathrm{g/mL}$: no visible growth\n\nAssume the organism identification is correct and that the antimicrobial agent is appropriate for testing this organism. Analyze the observed nonmonotonic growth pattern, considering the principles of dose–response and the definition of MIC in a correctly performed twofold dilution series. Which of the following is the most appropriate interpretation and action plan for this cefepime MIC, including logic for invalidating and repeating the test to address plausible technical artifacts that can generate such “skipped wells” (growth at higher concentrations after inhibition at lower ones)?\n\nA. Report the MIC as $0.125$ $\\mu\\mathrm{g/mL}$ because it is the lowest concentration with no visible growth; the anomalous higher-concentration growth can be ignored since the growth control is acceptable.\n\nB. Invalidate the cefepime MIC due to skipped wells and repeat the test; on repeat, verify twofold dilution accuracy and thorough mixing between transfers, use a fresh inoculum adjusted to $5 \\times 10^{5}$ CFU/mL, avoid air bubbles and edge-well evaporation, inspect for drug precipitation or misreading of turbidity, and confirm panel orientation; do not report an MIC until a monotonic inhibition pattern is obtained.\n\nC. Compute a geometric mean of the two blocks of “no growth” and “growth” to estimate an MIC around $0.5$ $\\mu\\mathrm{g/mL}$, which compensates for variability in the dilution series.\n\nD. Interpret this as heteroresistance and report the MIC as $2$ $\\mu\\mathrm{g/mL}$ with a comment on mixed subpopulations; no repeat is necessary.\n\nE. Attribute the pattern to “trailing” typical of bacteriostatic drugs and read the MIC at the first well with a noticeable reduction in turbidity, regardless of later wells regaining growth.",
            "solution": "The problem statement will first be validated for scientific soundness, consistency, and clarity before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Test:** Broth microdilution Minimum Inhibitory Concentration (MIC) test.\n- **Methodology:** Twofold serial dilution of a beta-lactam antimicrobial in cation-adjusted Mueller–Hinton broth.\n- **Inoculum:** Final density of approximately $5 \\times 10^{5}$ colony-forming units per milliliter (CFU/mL).\n- **Incubation:** $35\\,^{\\circ}\\mathrm{C}$ for $16$–$20$ h.\n- **MIC Definition:** The lowest antimicrobial concentration that prevents visible growth under correctly executed, standardized conditions.\n- **Isolate:** *Klebsiella pneumoniae*.\n- **Antimicrobial:** Cefepime.\n- **Observed Results (after $18$ h at $35\\,^{\\circ}\\mathrm{C}$):**\n    - Growth control: Visible turbidity (growth present).\n    - Sterility control: Clear (no growth).\n    - Cefepime concentrations and corresponding growth observations:\n        - $0.06$ $\\mu\\mathrm{g/mL}$: growth present\n        - $0.125$ $\\mu\\mathrm{g/mL}$: no visible growth\n        - $0.25$ $\\mu\\mathrm{g/mL}$: no visible growth\n        - $0.5$ $\\mu\\mathrm{g/mL}$: growth present\n        - $1$ $\\mu\\mathrm{g/mL}$: growth present\n        - $2$ $\\mu\\mathrm{g/mL}$: no visible growth\n        - $4$ $\\mu\\mathrm{g/mL}$: no visible growth\n        - $8$ $\\mu\\mathrm{g/mL}$: no visible growth\n- **Assumptions:** The organism identification is correct and the antimicrobial is appropriate for testing.\n- **Question:** Determine the most appropriate interpretation and action plan for the observed nonmonotonic growth pattern (skipped wells).\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is firmly grounded in the principles and standard practices of clinical microbiology. The test described (broth microdilution MIC), the organism (*K. pneumoniae*), the drug (cefepime, a beta-lactam), the medium (cation-adjusted Mueller–Hinton broth), inoculum density ($5 \\times 10^{5}$ CFU/mL), and incubation conditions ($35\\,^{\\circ}\\mathrm{C}$, $16$–$20$ h) are all standard as per guidelines from bodies like the Clinical and Laboratory Standards Institute (CLSI). The observed phenomenon of \"skipped wells\" is a known, albeit invalidating, artifact in this type of testing.\n2.  **Well-Posed:** The problem provides a specific set of experimental results and asks for the correct course of action according to established laboratory protocols. The problem is structured to have a single best-practice answer.\n3.  **Objective:** The problem statement is objective, using precise terminology and presenting quantitative data and qualitative observations without bias.\n4.  **Additional Checks:**\n    - The problem is self-contained. The successful growth and sterility controls confirm the basic validity of the medium and the aseptic technique for those specific wells, which is crucial for interpreting the rest of the panel.\n    - The \"contradiction\" is within the experimental results themselves ($0.125$ $\\mu\\mathrm{g/mL}$ inhibits but $0.5$ $\\mu\\mathrm{g/mL}$ does not), which is the very subject of the question. This is not a flaw in the problem statement but rather the central issue to be resolved.\n\n### Step 3: Verdict and Action\nThe problem statement is scientifically sound, well-posed, objective, and consistent with established laboratory diagnostic principles. It is **valid**. A solution will be derived.\n\n### Derivation of Solution\nThe core principle of antimicrobial susceptibility testing is the dose-response relationship. It is expected that as the concentration of an effective antimicrobial agent increases, its inhibitory effect will increase monotonically. An MIC is defined as the *lowest* concentration that completely inhibits visible growth. This definition implicitly requires that all concentrations at and above the MIC also inhibit growth.\n\nThe observed results are:\n- Growth at $0.06$ $\\mu\\mathrm{g/mL}$\n- No Growth at $0.125$ $\\mu\\mathrm{g/mL}$ and $0.25$ $\\mu\\mathrm{g/mL}$\n- Growth at $0.5$ $\\mu\\mathrm{g/mL}$ and $1$ $\\mu\\mathrm{g/mL}$\n- No Growth at $2$ $\\mu\\mathrm{g/mL}$, $4$ $\\mu\\mathrm{g/mL}$, and $8$ $\\mu\\mathrm{g/mL}$\n\nThis pattern is nonmonotonic. Growth appears in wells containing concentrations ($0.5$ and $1$ $\\mu\\mathrm{g/mL}$) that are higher than a concentration that showed complete inhibition ($0.125$ $\\mu\\mathrm{g/mL}$). This is known as \"skipped wells.\" According to standard laboratory practice (e.g., CLSI M07 guidelines), such a result is internally inconsistent and therefore invalid. The test cannot be reliably interpreted.\n\nThe most probable causes for skipped wells are technical errors, including:\n1.  **Contamination:** A resistant organism may have been accidentally introduced into the wells showing unexpected growth.\n2.  **Dilution Error:** A mistake during the serial dilution, leading to one or more wells having a significantly lower drug concentration than labeled.\n3.  **Inoculum Error:** Non-homogenous mixing of the bacterial suspension, leading to a much higher bacterial load being pipetted into certain wells.\n4.  **Reading Error:** Misinterpretation of debris, drug precipitate, or a poorly settled button of cells as true bacterial growth (turbidity).\n5.  **Panel/Plate Errors:** Physical issues with the microtiter plate, such as bubbles in wells or evaporation, or a simple error like reading the plate in the wrong orientation.\n\nLess common, but possible, are certain biological phenomena like the Eagle effect (paradoxical growth at very high concentrations) or heteroresistance. However, the Eagle effect typically occurs at concentrations much higher than the MIC. Heteroresistance is a possibility but should not be assumed as the primary cause without first rigorously excluding the far more common technical errors.\n\nThe correct and professionally responsible action is to acknowledge the invalidity of the test and repeat it. The repeat test must be performed with meticulous care to minimize the potential for technical errors, as these are the most likely cause. Reporting any MIC value from this invalid test would be a serious error, potentially leading to incorrect clinical treatment decisions.\n\n### Option-by-Option Analysis\n\n**A. Report the MIC as $0.125$ $\\mu\\mathrm{g/mL}$ because it is the lowest concentration with no visible growth; the anomalous higher-concentration growth can be ignored since the growth control is acceptable.**\nThis is **Incorrect**. This interpretation violates the fundamental definition of the MIC. The growth observed at $0.5$ $\\mu\\mathrm{g/mL}$ and $1$ $\\mu\\mathrm{g/mL}$ directly contradicts the conclusion that the organism is inhibited by $0.125$ $\\mu\\mathrm{g/mL}$. Ignoring contradictory data is scientifically indefensible and violates standard laboratory protocols. The valid growth control only confirms the organism can grow, not that the drug concentration series is behaving correctly.\n\n**B. Invalidate the cefepime MIC due to skipped wells and repeat the test; on repeat, verify twofold dilution accuracy and thorough mixing between transfers, use a fresh inoculum adjusted to $5 \\times 10^{5}$ CFU/mL, avoid air bubbles and edge-well evaporation, inspect for drug precipitation or misreading of turbidity, and confirm panel orientation; do not report an MIC until a monotonic inhibition pattern is obtained.**\nThis is **Correct**. This option accurately identifies the result as invalid due to skipped wells. It prescribes the correct course of action, which is to repeat the test. Crucially, it lists a comprehensive set of quality control checks to perform during the repeat test, addressing the most probable technical causes of the initial failure. This represents standard, best-practice clinical microbiology.\n\n**C. Compute a geometric mean of the two blocks of “no growth” and “growth” to estimate an MIC around $0.5$ $\\mu\\mathrm{g/mL}$, which compensates for variability in the dilution series.**\nThis is **Incorrect**. This proposes an arbitrary and scientifically baseless mathematical manipulation. There is no accepted principle that allows for \"averaging\" across contradictory results to generate a valid MIC. The data does not show \"variability\"; it shows a logical inconsistency pointing to a flawed experiment. Applying a formula to flawed data produces a meaningless result.\n\n**D. Interpret this as heteroresistance and report the MIC as $2$ $\\mu\\mathrm{g/mL}$ with a comment on mixed subpopulations; no repeat is necessary.**\nThis is **Incorrect**. While heteroresistance is a real phenomenon, jumping to this conclusion without first excluding the much more frequent possibility of technical error is poor scientific practice. Standard laboratory procedure requires ruling out technical artifacts by repeating the test. Only after a repeat test shows the same, validated anomalous pattern could a biological cause like heteroresistance be considered, often requiring further specialized testing. Reporting an MIC of $2$ $\\mu\\mathrm{g/mL}$ based on this single, flawed test is premature and unacceptable.\n\n**E. Attribute the pattern to “trailing” typical of bacteriostatic drugs and read the MIC at the first well with a noticeable reduction in turbidity, regardless of later wells regaining growth.**\nThis is **Incorrect**. Firstly, cefepime is a bactericidal antibiotic, and \"trailing\" (reduced but persistent growth across many concentrations) is not a characteristic phenomenon for this drug class, being more common with bacteriostatic agents like sulfonamides. Secondly, the observation is of complete inhibition followed by robust growth, which is the definition of a \"skipped well,\" not the hazy, partial inhibition characteristic of trailing.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "While determining the MIC of a single drug is a cornerstone of susceptibility testing, the future of treating resilient infections often lies in combination therapy. This practice moves into the domain of drug-drug interactions by exploring the checkerboard assay, a method used to assess whether two drugs work synergistically. You will calculate the Fractional Inhibitory Concentration (FIC) index, a key metric for quantifying synergy, and learn to apply objective criteria to interpret complex data that may include ambiguous, trailing growth .",
            "id": "5220390",
            "problem": "A clinical bacterium is tested by broth microdilution to determine the Minimum Inhibitory Concentration (MIC) of two antibiotics, Drug A and Drug B, alone and in combination using a checkerboard layout. The MIC is defined as the lowest concentration that prevents visible growth, and for optical-density-based reading, adopt the criterion that “no visible growth” corresponds to a measured optical density at $600$ nm, $OD_{600}$, that is less than or equal to $0.10$ times the positive growth control $OD_{600}$. A Fractional Inhibitory Concentration (FIC) is defined for each drug as the ratio of the drug’s concentration in the inhibitory combination well to its MIC when tested alone, and the FIC index (FICI) is defined as the sum of the two FICs.\n\nYou are provided the following scientifically consistent measurements:\n\n- Positive control $OD_{600}$ (no drug): $0.90$.\n- Negative control $OD_{600}$ (no inoculum): $0.05$.\n- Drug A alone (mg/L): $0$, $0.125$, $0.25$, $0.5$, $1$, $2$ with measured $OD_{600}$: $0.90$, $0.83$, $0.62$, $0.25$, $0.08$, $0.05$.\n- Drug B alone (mg/L): $0$, $0.5$, $1$, $2$, $4$, $8$ with measured $OD_{600}$: $0.90$, $0.88$, $0.70$, $0.40$, $0.07$, $0.05$.\n\nIn the checkerboard assay, the following combination wells were read (A mg/L, B mg/L) with measured $OD_{600}$:\n\n- $(0.125, 0.5) \\rightarrow 0.35$\n- $(0.125, 1) \\rightarrow 0.11$  (borderline haze)\n- $(0.125, 2) \\rightarrow 0.09$\n- $(0.25, 0.5) \\rightarrow 0.12$  (borderline haze)\n- $(0.25, 1) \\rightarrow 0.08$\n- $(0.25, 2) \\rightarrow 0.07$\n- $(0.5, 0.5) \\rightarrow 0.07$\n- $(0.5, 1) \\rightarrow 0.05$\n\nTasks:\n\n1. Using the stated MIC definition and the $OD_{600}$ threshold based on the positive control, determine the MIC of Drug A alone and Drug B alone.\n2. Identify which combination wells meet the “no visible growth” criterion. Trailing (hazy growth) is known to occur with these drugs; use the threshold strictly as defined to classify borderline wells objectively.\n3. Among the inhibitory combination wells, determine the combination to use for calculating the FICs by selecting the well that minimizes the sum of the FICs.\n4. Compute the MIC in combination for each drug, the FIC for Drug A, the FIC for Drug B, and the FIC index (FICI).\n\nRound your final numerical results to three significant figures. Express MIC values in mg/L. For the final answer, report the five values in the order: MIC of Drug A in combination, MIC of Drug B in combination, FIC of Drug A, FIC of Drug B, and FIC index (FICI).",
            "solution": "The fundamental base is the definition of the Minimum Inhibitory Concentration (MIC) as the lowest concentration that prevents visible growth. With optical density measurements, we operationalize “no visible growth” as $OD_{600} \\leq 0.10 \\times OD_{600,\\mathrm{pos\\ ctrl}}$. Given $OD_{600,\\mathrm{pos\\ ctrl}} = 0.90$, the inhibition threshold is\n$$\nOD_{600,\\mathrm{threshold}} = 0.10 \\times 0.90 = 0.09.\n$$\nAny well with $OD_{600} \\leq 0.09$ is classified as inhibited (no visible growth). Trailing (hazy growth) at higher $OD_{600}$ values (for example, $0.10$ to $0.20$ times $OD_{600,\\mathrm{pos\\ ctrl}}$) is treated as growth per this objective threshold.\n\nStep 1: Determine MIC for each drug alone.\n\n- Drug A alone: Measured $OD_{600}$ values at concentrations $0$, $0.125$, $0.25$, $0.5$, $1$, $2$ mg/L are $0.90$, $0.83$, $0.62$, $0.25$, $0.08$, $0.05$. The lowest concentration where $OD_{600} \\leq 0.09$ is $1$ mg/L (since at $0.5$ mg/L, $OD_{600} = 0.25 > 0.09$; at $1$ mg/L, $OD_{600} = 0.08 \\leq 0.09$). Therefore, $\\mathrm{MIC}_\\mathrm{A,alone} = 1$ mg/L.\n- Drug B alone: Measured $OD_{600}$ values at concentrations $0$, $0.5$, $1$, $2$, $4$, $8$ mg/L are $0.90$, $0.88$, $0.70$, $0.40$, $0.07$, $0.05$. The lowest concentration where $OD_{600} \\leq 0.09$ is $4$ mg/L. Therefore, $\\mathrm{MIC}_\\mathrm{B,alone} = 4$ mg/L.\n\nStep 2: Classify combination wells by the inhibition criterion.\n\nThe threshold is $0.09$. Examine each combination:\n\n- $(0.125, 0.5) \\rightarrow 0.35$: $0.35 > 0.09$ → growth.\n- $(0.125, 1) \\rightarrow 0.11$: $0.11 > 0.09$ → growth (borderline haze but above threshold, so not inhibited).\n- $(0.125, 2) \\rightarrow 0.09$: $0.09 \\leq 0.09$ → inhibited.\n- $(0.25, 0.5) \\rightarrow 0.12$: $0.12 > 0.09$ → growth (borderline haze, not inhibited).\n- $(0.25, 1) \\rightarrow 0.08$: $0.08 \\leq 0.09$ → inhibited.\n- $(0.25, 2) \\rightarrow 0.07$: $0.07 \\leq 0.09$ → inhibited.\n- $(0.5, 0.5) \\rightarrow 0.07$: $0.07 \\leq 0.09$ → inhibited.\n- $(0.5, 1) \\rightarrow 0.05$: $0.05 \\leq 0.09$ → inhibited.\n\nThus, the inhibitory wells are: $(0.125, 2)$, $(0.25, 1)$, $(0.25, 2)$, $(0.5, 0.5)$, $(0.5, 1)$.\n\nStep 3: Select the inhibitory well that minimizes the sum of the Fractional Inhibitory Concentrations (FICs). The Fractional Inhibitory Concentration for each drug is defined as\n$$\n\\mathrm{FIC}_\\mathrm{A} = \\frac{C_\\mathrm{A,combo}}{\\mathrm{MIC}_\\mathrm{A,alone}}, \\quad \\mathrm{FIC}_\\mathrm{B} = \\frac{C_\\mathrm{B,combo}}{\\mathrm{MIC}_\\mathrm{B,alone}},\n$$\nand the FIC index (FICI) is\n$$\n\\mathrm{FICI} = \\mathrm{FIC}_\\mathrm{A} + \\mathrm{FIC}_\\mathrm{B}.\n$$\nCompute for each inhibitory well, using $\\mathrm{MIC}_\\mathrm{A,alone} = 1$ mg/L and $\\mathrm{MIC}_\\mathrm{B,alone} = 4$ mg/L:\n\n- Well $(0.125, 2)$:\n$$\n\\mathrm{FIC}_\\mathrm{A} = \\frac{0.125}{1} = 0.125, \\quad \\mathrm{FIC}_\\mathrm{B} = \\frac{2}{4} = 0.5, \\quad \\mathrm{FICI} = 0.125 + 0.5 = 0.625.\n$$\n- Well $(0.25, 1)$:\n$$\n\\mathrm{FIC}_\\mathrm{A} = \\frac{0.25}{1} = 0.25, \\quad \\mathrm{FIC}_\\mathrm{B} = \\frac{1}{4} = 0.25, \\quad \\mathrm{FICI} = 0.25 + 0.25 = 0.50.\n$$\n- Well $(0.25, 2)$:\n$$\n\\mathrm{FIC}_\\mathrm{A} = 0.25, \\quad \\mathrm{FIC}_\\mathrm{B} = 0.5, \\quad \\mathrm{FICI} = 0.75.\n$$\n- Well $(0.5, 0.5)$:\n$$\n\\mathrm{FIC}_\\mathrm{A} = \\frac{0.5}{1} = 0.5, \\quad \\mathrm{FIC}_\\mathrm{B} = \\frac{0.5}{4} = 0.125, \\quad \\mathrm{FICI} = 0.5 + 0.125 = 0.625.\n$$\n- Well $(0.5, 1)$:\n$$\n\\mathrm{FIC}_\\mathrm{A} = 0.5, \\quad \\mathrm{FIC}_\\mathrm{B} = 0.25, \\quad \\mathrm{FICI} = 0.75.\n$$\n\nThe minimal $\\mathrm{FICI}$ is $0.50$ at well $(0.25, 1)$.\n\nStep 4: Report the MICs in combination and FIC values from the selected well.\n\n- MIC of Drug A in combination: $0.25$ mg/L.\n- MIC of Drug B in combination: $1$ mg/L.\n- $\\mathrm{FIC}_\\mathrm{A} = 0.25$.\n- $\\mathrm{FIC}_\\mathrm{B} = 0.25$.\n- $\\mathrm{FICI} = 0.50$.\n\nRounding to three significant figures, these are $0.250$, $1.00$, $0.250$, $0.250$, and $0.500$, respectively.\n\nInterpretation of borderline trailing: Wells such as $(0.125, 1)$ with $OD_{600} = 0.11$ and $(0.25, 0.5)$ with $OD_{600} = 0.12$ show haze (trailing) but exceed the objective threshold of $0.09$, and therefore must be classified as growth rather than inhibition. This prevents underestimation of MICs due to trailing and ensures that FIC calculations are based on wells meeting the strict inhibition criterion.",
            "answer": "$$\\boxed{\\begin{pmatrix}0.250 & 1.00 & 0.250 & 0.250 & 0.500\\end{pmatrix}}$$"
        }
    ]
}